Bank of New York Mellon Corp Purchases 114,762 Shares of Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX)

Bank of New York Mellon Corp boosted its position in Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX) by 35.7% in the second quarter, according to its most recent filing with the SEC. The institutional investor owned 435,958 shares of the company’s stock after purchasing an additional 114,762 shares during the period. Bank of New York Mellon Corp’s holdings in Lineage Cell Therapeutics were worth $435,000 as of its most recent SEC filing.

A number of other institutional investors have also added to or reduced their stakes in LCTX. Fifth Third Wealth Advisors LLC bought a new position in shares of Lineage Cell Therapeutics during the 1st quarter valued at approximately $30,000. DCF Advisers LLC grew its position in shares of Lineage Cell Therapeutics by 14.5% during the 4th quarter. DCF Advisers LLC now owns 94,751 shares of the company’s stock valued at $103,000 after acquiring an additional 12,000 shares during the period. Price T Rowe Associates Inc. MD grew its position in shares of Lineage Cell Therapeutics by 77.5% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 161,314 shares of the company’s stock valued at $239,000 after acquiring an additional 70,418 shares during the period. Finally, Comerica Bank grew its position in shares of Lineage Cell Therapeutics by 84,745.8% during the 1st quarter. Comerica Bank now owns 250,295 shares of the company’s stock valued at $370,000 after acquiring an additional 250,000 shares during the period. 62.47% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Separately, Craig Hallum started coverage on shares of Lineage Cell Therapeutics in a research report on Tuesday, August 20th. They set a “buy” rating and a $4.00 target price for the company.

Lineage Cell Therapeutics Stock Performance

Shares of LCTX stock opened at $0.90 on Wednesday. The company has a market cap of $170.01 million, a P/E ratio of -6.43 and a beta of 1.26. Lineage Cell Therapeutics, Inc. has a 12 month low of $0.77 and a 12 month high of $1.61.

Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) last announced its quarterly earnings results on Thursday, August 8th. The company reported ($0.03) EPS for the quarter, beating analysts’ consensus estimates of ($0.04) by $0.01. The company had revenue of $1.41 million for the quarter, compared to analysts’ expectations of $1.28 million. Lineage Cell Therapeutics had a negative net margin of 391.00% and a negative return on equity of 36.30%. As a group, research analysts forecast that Lineage Cell Therapeutics, Inc. will post -0.12 EPS for the current year.

Lineage Cell Therapeutics Profile

Lineage Cell Therapeutics, Inc, a clinical-stage biotechnology company, develops novel cell therapies for unmet medical needs in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries; and VAC, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer.